Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEGENE gene therapy for Artemis-deficient SCID
2024-513652-15-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2023
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Artegene in Artemis-deficient severe combined immunodeficiency (Artemis-SCID), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Safety and efficacy of ARTEGENE drug product. Planned start Jul 2023; status: authorised.
02
Drugs
Artegene
03
Conditions
Artemis-deficient severe combined immunodeficiency (Artemis-SCID)
Beyond the preview
Go deeper on 2024-513652-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513652-15-00.